Cardiomyopathy

The cardiac myosin inhibitor is expected to be available in the US in the second half of January 2026.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

Intranasal etripamil was approved to self-treat episodes of paroxysmal supraventricular tachycardia, supported by phase 3 RAPID trial data.

Long-term data suggest stress echocardiography can uncover impaired exercise capacity and predict worse outcomes in patients.

After 8 months of treatment with mavacamten, 5% of patients developed new atrial fibrillation or flutter and 4% developed heart failure.

Papillary muscle scarring has a substantial association with both cardiovascular mortality and arrhythmia.